Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 14/20 | 0.68 |
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.68 |
| ▸ | HRH1 | P35367 | 7/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13458766 | 0.83 | — | — | |
| SCHEMBL5911593 | 0.81 | HRH2 (0.70) | HRH2HRH4HRH1CYP1A2NOS1 | |
| Amthamine SCHEMBL400272 | 0.81 | HRH2 (1.00) | HRH2HRH4HRH1CYP1A2NOS1 | |
| Amthamine SCHEMBL7443757 | 0.79 | HRH2 (0.96) | HRH2HRH4HRH1CYP1A2NOS1 | |
| SCHEMBL11397758 | 0.79 | HRH2 (0.68) | HRH2HRH4HRH1CYP1A2NOS1 | |
| SCHEMBL27655314 | 0.79 | HRH2 (0.61) | HRH2HRH4HRH1CYP1A2NOS1 | |
| SCHEMBL261442 | 0.78 | SRC (0.47) | HRH2HRH4HRH1CYP1A2 | |
| SCHEMBL263398 | 0.78 | ALDH1A1 (0.45) | HRH2HRH4HRH1CYP1A2ALDH1A1 | |
| Bromide SCHEMBL11173485 | 0.78 | HRH2 (0.66) | HRH2HRH4HRH1CYP1A2NOS1 | |
| SCHEMBL7443479 | 0.78 | HRH2 (0.78) | HRH2HRH4HRH1CYP1A2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753734-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2007-02-21 | — | — | EP | claimed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| CN-119019361-A | Synthesis method of 5-hydroxyethyl-4-methylthiazole | 山东吉田生物科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-12075656-B2 | Circuits including non-linear components for electronic devices | AMORPHYX, INCORPORATED (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2023141262-A1 | BAX ACTIVATORS AND USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2023-07-27 | — | — | WO | disclosed |
| US-20230232663-A1 | CIRCUITS INCLUDING NON-LINEAR COMPONENTS FOR ELECTRONIC DEVICES | AMORPHYX, INCORPORATED (US) | 2023-07-20 | — | — | US | disclosed |
| CN-116075936-A | Circuit comprising nonlinear components for electronic devices | 非结晶公司 | 2023-05-05 | — | — | CN | disclosed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-8134010-B2 | 4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenylamine; N-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-acetamide; or4-Methyl-5-(2-nitrooxy-ethyl)-2-(4-nitro-phenyl)-thiazole; cardiovascular, gastrointestinal, inflammatory, respiratory disease | RENOPHARM LTD. (IL) | 2012-03-13 | — | — | US | disclosed |
| US-7968575-B2 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2011-06-28 | — | — | US | disclosed |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105065-A2 | THIAZOLE-BASED NITRIC OXIDE DONORS FOR TREATING INFLAMMATORY BOWEL DISEASES | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
| EP-0794185-A1 | BICYCLIC THIAZOLE COMPOUND | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-09-10 | — | — | EP | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | NOS2, NOS1, NOS3 | HRH2 389/4885HRH4 707/4885HRH1 927/4885 |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | NOS2, NOS1, NOS3 | HRH2 219/4885HRH4 474/4885HRH1 541/4885 |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | HRH2 669/4885HRH4 829/4885HRH1 1048/4885 |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | NOS2, NOS1, NOS3 | HRH2 258/4885HRH4 729/4885HRH1 743/4885 |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | NOS1, NOS2, NOS3 | HRH2 623/4885HRH4 867/4885HRH1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.